Posted by Michael Wonder on 08 Aug 2016
CADTH issues final pERC outcome for Yondelis (trabectedin)
5 August 2016 - CADTH has published pERC's final recommendation on the use of trabectedin for patients with metastatic liposarcoma or leiomyosarcoma.
The pERC has not recommended the use of trabectedin for the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy on the basis that there is no net clinical benefit when compared with dacarbazine.
